Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma

Refractory or relapsed diffuse large B-cell lymphoma (DLBCL) is challenging to treat in general and progression in the central nervous system (CNS) is associated with particularly dismal outcomes. Indeed, the median survival of patients diagnosed with CNS relapse is typically 2-4 months. The incidence of CNS relapse is 2-5% in unselected patient cohorts treated with modern immunochemotherapy, presenting a challenge for risk prediction. Individual risk factors for CNS relapse are well established, and include clinical parameters such as age, stage, elevated lactate dehydrogenase and performance status. Moreover, the involvement of certain extranodal sites such as uterus/testis or kidney/adrenal gland confers higher risk of CNS relapse. These individual clinical risk factors have been integrated into a risk score (CNS International Prognostic Index [CNS-IPI]). Molecular attributes such as double-hit translocation status, BCL2/MYC dual protein expression as well as the activated B-cell-like (ABC) subtype (or non-germinal center B [GCB]), have also been associated with a higher risk of CNS relapse. However, the major shortcoming of available risk prediction models is their limited discriminative power. While the CNS-IPI classifies 12% of patients into the high-risk group, only 10% of patients within this high-risk group experience CNS relapse. Herein, to comprehensively assess molecular determinants of CNS relapse, we chose three distinct approaches. Firstly, we performed exome sequencing in paired tissue biopsies (peripheral and CNS parenchymal tumors) and reconstructed clonal phylogenies that underlie CNS invasion. Secondly, we assembled a dataset to assess the association of specific gene mutations with CNS relapse. Lastly, we performed gene expression and pathway analysis on an enriched cohort of diagnostic tissue samples from 222 patients with diverging clinical outcomes. An overview of all samples used in this study is shown in the Online Supplementary Figure S1. In order to describe changes in clonal structure associated with CNS relapse, we used the PyClone computational tool to infer clonal structures in five paired CNS samples (Online Supplementary Table S1). Recurrent gene mutations included PIM1 (n=4), CD44 (n=3), ETV6 (n= 3), MALAT1 (n=3), ARHGAP5 (n=2), CD79B (n=2), CXCR4 (n=2) and RUNX1T1 (n=2). We observed striking clonal divergence in all five cases, with biopsies from the time of CNS invasion characterized by discrete sets of mutations (Figure 1). In general, the expanding subclones were not sampled at the time point of diagnosis, with the main exception being case LY_CNSrel_006. The number of mutations found in CNS-relapsing clones tended to be higher than the number of shared mutations, and higher than the number of mutations exclusively found at diagnosis (Online Supplementary Figure S2). The most frequently mutated gene was PIM1, with 22 exonic, intronic and untranslated region mutations identified in samples from four patients, in keeping with PIM1 being recognized as a known target of aberrant somatic hypermutation in DLBCL. These mutations were mostly subclonal (95%), identified in either expanding (14 of 22 mutations, 64%) or extinguished clones (seven of 22 mutations, 32%). The ETS family member transcription factor ETV6 was found to be mutated in expanding clones in two cases, and in an ancestral clone in another case, with all mutations mapping to the exon 1 donor splice site. Our findings document the existence of intratumoral heterogeneity that is associated with the emergence of subclones that are observed in the CNS. They also suggest that the disease leading to relapse has features that are distinct from the disease found at primary diagnosis. Next, we asked whether a larger cohort of diagnostic samples could delineate gene mutations associated with either CNS or systemic relapse. We compiled mutation data from 223 diagnostic DLBCL samples, derived from several datasets of both population-based and clinical trial series. Information on 45 genes was available for 72 cases with CNS relapse, 62 cases with systemic relapse and 89 cases without relapse (Online Supplementary Table S2). The strongest signal for enrichment within cases with subsequent CNS relapse was found for MYD88, although this gene was almost as frequently mutated in cases with subsequent systemic relapse (Figure 2). On the other hand, several gene mutations appeared most robustly associated with systemic relapse, and were comparatively uncommon in cases with subsequent CNS relapse. This pattern was most striking for TP53, with mutations found in 45% of patients experiencing systemic relapse, in 20% of patients with no relapse, and in only 11% of patients with subsequent CNS relapse. Furthermore, we found that certain gene mutations were relatively depleted in CNS relapse cases, compared to cases with either systemic or no relapse. The most striking example was KMT2D, mutated in 22% of patients with CNS relapse, compared to 39% and 37% of patients with no relapse and systemic relapse, respectively. Lastly, we asked whether specific pathways were enriched in diagnostic samples from patients who subsequently experienced either CNS or systemic relapse. We included a total of 222 patients with samples available for gene expression profiling: 50 patients with CNS relapse (n=39) or CNS involvement documented at diagnosis (n=11), 64 patients with systemic relapse and 108 patients without relapse (Online Supplementary Table S3). We performed gene set enrichment analysis to identify biological processes deregulated in the three risk groups (Online Supplementary Table S4). Interestingly, we observed a significant downregulation of pathways in ABC-DLBCL when comparing systemic versus no relapse, and an upregulation of pathways in GCBDLBCL (Figure 3A). Downregulation of pathways was also observed in CNS versus no relapse in ABC-DLBCL but not GCB-DLBCL. We observed that systemic relapse in GCB-DLBCL appeared to be driven by MYC, metabolic and protein translation signatures, to a higher degree than CNS relapse (Figure 3B). We assessed whether the double-hit signature allowed the delineation of varying risks of CNS and/or systemic relapse in our cohort. Overall, 39 of 90 classifiable GCB cases (43%) were positive for a double-hit signature. The percentage of double-hit signature-postive-positive cases was similar between systemic (64%) and CNS relapse (58%), and lower in cases without relapse (29%, χ test P=0.008, Online Supplementary Figure S3). These results link expression of the DHIT signature with CNS relapse, mirroring the increased risk of CNS relapse conferred by dual expression of MYC and BCL2. ABC-DLBCL cases with subsequent relapse were characterized by depletion of stromal signatures, an effect that was most pronounced in those ABC-DLBCL cases with systemic relapse. In summary, while cases with subsequent CNS relapse displayed similar pathway enrichment patterns to cases with subsequent systemic relapse, there are like-

[1]  L. Sehn,et al.  Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. , 2019, Blood.

[2]  Gary D Bader,et al.  Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap , 2019, Nature Protocols.

[3]  Ryan D. Morin,et al.  Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[5]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[6]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[7]  Rebecca F. Halperin,et al.  Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum , 2017, Oncotarget.

[8]  L. Sehn,et al.  The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. , 2017, European journal of cancer.

[9]  R. Gascoyne,et al.  CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Millenson,et al.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Ruiz,et al.  Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis , 2016, Leukemia.

[12]  R. Gascoyne,et al.  Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. , 2016, Blood.

[13]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[14]  R. Gascoyne,et al.  Cell of origin of transformed follicular lymphoma. , 2015, Blood.

[15]  Nilgun Donmez,et al.  Clonality inference in multiple tumor samples using phylogeny , 2015, Bioinform..

[16]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[17]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[18]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[19]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[20]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[21]  R. Kridel,et al.  Prevention of CNS relapse in diffuse large B-cell lymphoma. , 2011, The Lancet. Oncology.

[22]  John K Kruschke,et al.  Bayesian Assessment of Null Values Via Parameter Estimation and Model Comparison , 2011, Perspectives on psychological science : a journal of the Association for Psychological Science.

[23]  Rafael A. Irizarry,et al.  A framework for oligonucleotide microarray preprocessing , 2010, Bioinform..

[24]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[25]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[26]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[27]  N. Schmitz,et al.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.

[28]  J. Friedberg,et al.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Yonina C. Eldar,et al.  A fast and flexible method for the segmentation of aCGH data , 2008, ECCB.

[30]  N. Schmitz,et al.  Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. Glas,et al.  Primary testicular diffuse large B‐cell lymphomas have activated B‐cell‐like subtype characteristics , 2006, The Journal of pathology.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[34]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.